China-based in vitro diagnostics (IVD) maker UB Biotechnology (Zhejiang) Co., Ltd has reportedly raised “tens of millions” of renminbi in a Series A financing round, led solely by Yuanbio Venture Capital. The proceeds will be directed towards research and development and market development for its flow cytometry technology platform.
Company Profile
Founded in 2017, UB Bio is known for its innovative immunocyte detection solutions, including its mitochondrial detection kit and supporting flow cytometer, which are the first of their kind to obtain market approval in China. The company specializes in providing comprehensive solutions for precision immune status evaluation in medical institutions, targeting infectious diseases, auto-immune diseases, and tumors.
Future Plans
With the new funding, UB Biotechnology plans to enhance its flow cytometry platform, furthering its commitment to advancing precision medicine. The company aims to expand its market presence and continue developing innovative diagnostic tools that improve patient outcomes through accurate immune status assessments.-Fineline Info & Tech
